-
How Endo's FDA Committee Vote Affects Egalet
Wednesday, March 15, 2017 - 10:38am | 368“After two days of data presentations, the FDA Advisory Committee voted 18-8 (1 abstention) that the benefits of reformulated, crush-resistant Opana ER no longer outweigh the risks,” Cantor Fitzgerald’s Chiara Russo said in a note. The analyst maintained an Overweight rating on...
-
For Egalet, Clinical Delays Outweigh Solid Q4 And Arymo Launch
Monday, March 13, 2017 - 1:45pm | 305Cantor Fitzgerald cut its price target on Egalet Corp (NASDAQ: EGLT) shares by $2 to $13 on the delay of clinical progress for Egalet-002, which is now expected to file an NDA in 2019 versus previous guidance of mid-2017. However, Chiara Russo maintained an Overweight rating on the stock, given the...
-
Exclusive: Egalet CEO Talks Drug Approvals, 21st Century Cures Act And Winning The War On Opioid Abuse
Thursday, January 19, 2017 - 9:37am | 1104Egalet Corp (NASDAQ: EGLT) was surely one of the most watched biotechs of the fourth quarter of 2016. After the company announced the Food and Drug Administration would miss its PDUFA decision date for Egalet’s opioid-based pain medication ARYMO ER, investors waited impatiently for news of a...
-
Exclusive: Egalet CFO Talks 'Hot Button' Rx Abuse-Deterrence, Pipeline And Multimillion-Dollar Financing
Friday, September 9, 2016 - 11:25am | 694Egalet Corp (NASDAQ: EGLT) is a U.S.-based specialty pharmaceutical company that focus on treatments for pain and other conditions. The company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. Benzinga had the privilege of chatting with the company...